[1]
|
American Diabetes Association. American Diabetes Associa-tion Standards of Medical Care in Diabetes-2019[J]. Diabetes Care, 2019, 42:S1-S186. doi: 10.2337/dc19-Sint01 |
[2]
|
中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志, 2018, 10:4-67. |
[3]
|
Davies MJ, D'Alessio DA, Fradkin J, et al.Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J]. Diabetes Care, 2018, 41:2669-2701. doi: 10.2337/dci18-0033 |
[4]
|
Jorsal A, Kistorp C, Holmager P, et al. Effect of lirag-lutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial[J]. Eur J Heart Fail, 2017, 19:69-77. doi: 10.1002/ejhf.657 |
[5]
|
Margulies KB, Hernandez AF, Redfield MM, et al.Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction:A Randomized Clinical Trial[J]. JAMA, 2016, 316:500-508. doi: 10.1001/jama.2016.10260 |
[6]
|
Marso SP, Bain SC, Consoli A, et al.Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes[J]. N Engl J Med, 2016, 375:1834-1844. doi: 10.1056/NEJMoa1607141 |
[7]
|
Marso SP, Daniels GH, Brown-Frandsen K, et al.Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes[J]. N Engl J Med, 2016, 375:311-322. doi: 10.1056/NEJMoa1603827 |
[8]
|
Neal B, Perkovic V, Mahaffey KW, et al.Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes[J]. N Engl J Med, 2017, 377:644-657. doi: 10.1056/NEJMoa1611925 |
[9]
|
Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME)[J]. Cardiovasc Diabetol, 2014, 13:102. doi: 10.1186/1475-2840-13-102 |
[10]
|
Abd El Aziz MS, Kahle M, Meier JJ, et al.A meta-analysis comparing clinical effects of short-or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients[J]. Diabetes Obes Metab, 2017, 19:216-227. doi: 10.1111/dom.12804 |
[11]
|
Bowman L, Mafham M, Wallendszus K, et al.Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus[J]. N Engl J Med, 2018, 379:1529-1539. doi: 10.1056/NEJMoa1804988 |
[12]
|
Gaziano JM, Brotons C, Coppolecchia R, et al.Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE):a randomised, double-blind, placebo-controlled trial[J]. Lancet, 2018, 392:1036-1046. doi: 10.1016/S0140-6736(18)31924-X |
[13]
|
Group ASC, Bowman L, Mafham M, et al.Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus[J]. N Engl J Med, 2018, 379:1529-1539. doi: 10.1056/NEJMoa1804988 |
[14]
|
朱铁楠.抗血小板治疗实验室监测之我见[J].协和医学杂志, 2018, 9:123-126. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xhyx201802006 |
[15]
|
Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose:analysis of individual patient data from randomised trials[J]. Lancet, 2018, 392:387-399. doi: 10.1016/S0140-6736(18)31133-4 |